Short-term evolution of Mpox-specific IgG and neutralizing antibodies among individuals undergoing MVA-BN vaccination
Authors:
Open Access
- 31 January 2025
- journal article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 153, 107830
Abstract
No abstract availableKeywords
Funding Information
- National Science and Technology Council
This publication has 35 references indexed in Scilit:
- Monkeypox virus A29L protein as the target for specific diagnosis and serological analysisApplied Microbiology and Biotechnology, 2024
- Decline of Mpox Antibody Responses After Modified Vaccinia Ankara–Bavarian Nordic VaccinationJAMA, 2024
- Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort studyeClinicalMedicine, 2024
- Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individualsCell Host & Microbe, 2023
- Smallpox vaccination‐elicited antibodies cross‐neutralize 2022‐Monkeypox virus Clade IIJournal of Medical Virology, 2023
- Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigensiScience, 2023
- The first imported case of monkeypox in TaiwanJournal of the Formosan Medical Association, 2022
- The WHO Declaration of Monkeypox as a Global Public Health EmergencyJAMA, 2022
- Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus InfectionsCell, 2016
- Immunity from Smallpox Vaccine Persists for Decades: A Longitudinal StudyThe American Journal of Medicine, 2008